Reaction

Lung Diffusion Test Decreased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 391 reports · 19 co-occurring drugs

As of the last recalculation, Lung Diffusion Test Decreased appears in 391 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is NINTEDANIB (PRR 129.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Nintedanib64129.7130.0
Pirfenidone5787.187.2
Ciclesonide2186.786.8
Calcitriol Capsules 0.25 Mcg2570.971.0
Calcitriol Capsules 0.5 Mcg2570.971.0
Calcitriol2570.070.1
Rosuvastatin Calcium3265.865.8
Fluticasone Propionate And Salmeterol Xinafoate6265.165.2
Omalizumab7053.053.1
Rabeprazole2050.650.6
Timolol1149.849.9
Mepolizumab4047.647.7
Tiotropium Bromide7938.238.2
Loperamide Hydrochloride Oral737.137.2
Doxazosin Mesylate2234.334.3
Imatinib1134.134.2
Fluticasone Furoate And Vilanterol Trifenatate2031.131.2
Sitagliptin And Metformin Hydrochloride1230.530.5
Bleomycin Sulfate526.126.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.